Zacks: Analysts Anticipate Spark Therapeutics, Inc. (ONCE) to Announce -$1.93 Earnings Per Share

Brokerages expect that Spark Therapeutics, Inc. (NASDAQ:ONCE) will announce ($1.93) earnings per share for the current fiscal quarter, Zacks reports. Five analysts have made estimates for Spark Therapeutics’ earnings. The highest EPS estimate is ($1.75) and the lowest is ($2.05). Spark Therapeutics posted earnings per share of ($1.07) in the same quarter last year, which would indicate a negative year over year growth rate of 80.4%. The company is expected to report its next earnings report on Thursday, November 2nd.

On average, analysts expect that Spark Therapeutics will report full year earnings of ($7.65) per share for the current fiscal year, with EPS estimates ranging from ($8.08) to ($6.97). For the next fiscal year, analysts anticipate that the company will post earnings of ($5.16) per share, with EPS estimates ranging from ($7.92) to ($3.01). Zacks’ EPS averages are an average based on a survey of research firms that that provide coverage for Spark Therapeutics.

Spark Therapeutics (NASDAQ:ONCE) last announced its quarterly earnings results on Wednesday, August 2nd. The biotechnology company reported ($1.89) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.75) by ($0.14). The business had revenue of $1.48 million for the quarter, compared to the consensus estimate of $1.33 million. Spark Therapeutics had a negative net margin of 962.72% and a negative return on equity of 59.74%. The company’s revenue for the quarter was up 14.7% compared to the same quarter last year. During the same period in the previous year, the company earned ($1.04) earnings per share.

ONCE has been the subject of a number of recent analyst reports. William Blair initiated coverage on Spark Therapeutics in a research report on Wednesday, June 28th. They issued an “outperform” rating for the company. Zacks Investment Research cut Spark Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, July 12th. BidaskClub raised Spark Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, June 22nd. Jefferies Group LLC reissued a “buy” rating and issued a $85.00 price objective on shares of Spark Therapeutics in a research report on Monday, July 24th. Finally, ValuEngine cut Spark Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 20th. Two research analysts have rated the stock with a sell rating, two have given a hold rating and fourteen have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $83.77.

In other Spark Therapeutics news, Director Anand Mehra sold 211,858 shares of Spark Therapeutics stock in a transaction dated Monday, July 24th. The stock was sold at an average price of $70.15, for a total transaction of $14,861,838.70. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Katherine A. High sold 10,000 shares of Spark Therapeutics stock in a transaction dated Monday, June 19th. The shares were sold at an average price of $60.00, for a total value of $600,000.00. Following the transaction, the insider now owns 220,000 shares of the company’s stock, valued at approximately $13,200,000. The disclosure for this sale can be found here. Insiders have sold a total of 374,160 shares of company stock valued at $26,723,411 in the last quarter. Company insiders own 7.30% of the company’s stock.

Several institutional investors have recently made changes to their positions in ONCE. Ameritas Investment Partners Inc. increased its stake in shares of Spark Therapeutics by 23.6% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,040 shares of the biotechnology company’s stock valued at $122,000 after purchasing an additional 389 shares in the last quarter. Cubist Systematic Strategies LLC purchased a new position in shares of Spark Therapeutics in the 2nd quarter valued at about $143,000. BNP Paribas Arbitrage SA increased its stake in shares of Spark Therapeutics by 530.1% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 2,911 shares of the biotechnology company’s stock valued at $174,000 after purchasing an additional 2,449 shares in the last quarter. Pacad Investment Ltd. increased its stake in shares of Spark Therapeutics by 75.0% in the 2nd quarter. Pacad Investment Ltd. now owns 3,500 shares of the biotechnology company’s stock valued at $209,000 after purchasing an additional 1,500 shares in the last quarter. Finally, Highbridge Capital Management LLC purchased a new position in shares of Spark Therapeutics in the 1st quarter valued at about $227,000. Hedge funds and other institutional investors own 91.01% of the company’s stock.

Shares of Spark Therapeutics (ONCE) traded down 1.35% on Tuesday, hitting $81.95. The stock had a trading volume of 220,851 shares. The company’s 50 day moving average price is $77.32 and its 200-day moving average price is $62.21. Spark Therapeutics has a 12 month low of $35.07 and a 12 month high of $86.86. The company’s market cap is $2.56 billion.

ILLEGAL ACTIVITY WARNING: This report was first reported by Markets Daily and is the property of of Markets Daily. If you are viewing this report on another domain, it was copied illegally and reposted in violation of U.S. & international copyright law. The correct version of this report can be accessed at https://www.themarketsdaily.com/2017/09/12/zacks-analysts-anticipate-spark-therapeutics-inc-once-to-announce-1-93-earnings-per-share.html.

Spark Therapeutics Company Profile

Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.

Get a free copy of the Zacks research report on Spark Therapeutics (ONCE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply